Feed ALKS
AL

Alkermes

ALKS · NASDAQ

$43.39 -6.53% (-$3.03)
1M -10.22%
Market Cap $7.84B
P/E Ratio 118.51x
Div. Yield -
ROE 3.72%

Bulios Fair Price

$40.35

7.0% downside

Current Price

$43.39

Undervalued Fair Value Overvalued

According to Bulios Fair Price, ALKS is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
4/9
Valuation
19 /100
Expensive
P/S 4.70x
P/E 118.51x
P/B 4.33x
Growth
74 /100
Growing
Book val. growth 20.35%
Rev. growth 9.90%
FCF growth N/A
Profitability
59 /100
Moderate
Op. margin 7.03%
Gross margin 84.56%
FCF margin 13.29%
Quality
15 /100
Poor
ROA 1.51%
ROIC 2.12%
Asset turnover 0.38x
Debt
43 /100
Moderate
Int. coverage 2.65x
Debt/Equity 0.87x
Net debt/EBITDA 4.87x
Stability
19 /100
Unstable
EPS volatility 192.52%
Beta 0.26x
Profitable years 3

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about ALKS
Online

About the company

Alkermes plc is a global biotechnology company focused on the development and manufacturing of innovative medicines for the treatment of neuropsychiatric and oncological diseases. Founded in 1987 and headquartered in Dublin, Ireland, Alkermes specializes in developing drugs for the treatment of mental health disorders such as schizophrenia, depression, and addiction, as well as cancer therapies. The company is known for its technology in the production of long-acting injectable medications, aiming to provide patients with effective and accessible treatment options.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Blair Jackson

Employees

2,050

Headquarters

Dublin

Upcoming events

28 OCT

Earnings

Upcoming earnings report

38d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.